English
Regional settings| Spread | 0.176 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ £5,000.00 Short position overnight fee ~ £4,000.00 | -0.025295% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ £5,000.00 Short position overnight fee ~ £4,000.00 | 0.003377% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | GBP | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 22.512 |
| Open | 22.262 |
| 1-Year Change | -19.35% |
| Day's Range | 22.262 - 22.712 |
Oxford Instruments plc is a United Kingdom-based provider of technology products and services to the industrial companies and scientific research communities across the world. The Company's segments include Materials & Characterisation, Research & Discovery and Service & Healthcare. Materials & Characterisation segment comprises a group of businesses focusing on applied research and design and commercial customers, enabling the fabrication and characterization of materials and devices down to the atomic scale. Research & Discovery segment comprises a group of businesses providing solutions that create environments and enable measurements down to the molecular and atomic level, which are used in fundamental research. Service & Healthcare segment provides customer service and support for the Company's products and the service of third-party healthcare imaging systems. Its product categories include Atomic Force Microscopy, Electron Microscopy and Low-Temperature Systems, among others.
BRIEF: For the six months ended 30 September 2021, Oxford Instruments plc revenues increased 21% to £170.1M. Net income increased 4% to £16.5M. Revenues reflect Materials & Characterisation segment increase of 30% to £84.9M, Research & Discovery segment increase of 17% to £56.3M, Service & Healthcare segment increase of 8% to £28.9M. Net income was partially offset by Service & Healthcare segment income decrease of 1% to £8.9M.
